Point72 Asset Management
APLS

Point72 Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Point72 Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75,000
Closed -$2.47M – 1078
2021
Q3 		$2.47M Buy
+75,000
New +$4.21M 0.01% 770

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management's APLS Position: Q1 2026 in Review

Point72 Asset Management increased its Apellis Pharmaceuticals (APLS) stake by 600% in Q1 2026, buying an estimated $77.3M and bringing the position to 4,183,918 shares worth $168M. The position accounts for 0.22% of the portfolio, ranked #74.

Point72 Asset Management first reported a position in APLS in Q4 2018 and has held it in 15 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Point72 Asset Management held 4,183,918 shares of Apellis Pharmaceuticals worth $168M as of Q1 2026.
  • Point72 Asset Management bought 3,586,246 Apellis Pharmaceuticals shares in Q1 2026, an estimated $77.3M.
  • Apellis Pharmaceuticals made up 0.22% of Point72 Asset Management's portfolio in Q1 2026, its #74 holding.
  • Point72 Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.